Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

“We see people coming back with under-expanded stents, and we know that's due to ... or truly uncrossable at baseline.” According to Abbott, the Diamondback 360 system—which it acquired ...

Growing cases of coronary artery diseases propel the coronary stent market in the United States. Favorable government support ...

T o address chronic limb-threatening ischemia—a serious condition in which patients have majorly blocked blood flow to their hands, legs, or feet—Abbott’s FDA-approved, first-of-its-kind dissolvable ...

Abbott, Boston Scientific, Medtronic, Biotronik, Terumo Corporation, and B. Braun SE are the leading global coronary stents market companies. These vendors are continuously developing and ...

For patients with severely calcified coronary lesions, routine treatment with orbital atherectomy prior to drug-eluting stent ...

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...